• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding Div RTS (OP:RHHVF)

    404.18 +1.96 (+0.49%)
    Streaming Delayed Price Updated: 2:03 PM EDT, Jun 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding Div RTS

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
    GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
    Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
    Via MarketBeat
    News headline image
    Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗
    Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
    Via Benzinga
    News headline image
    Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗
    Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen... 
    Via Benzinga
    News headline image
    Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗
    Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti 
    Via Benzinga
    News headline image
    Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗
    Roche Holding AG (OTC: RHHBY) has agreed to 
    Via Benzinga
    News headline image
    Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗
    Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
    Via Benzinga
    News headline image
    Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗
    Roche Holdings AG's (OTC: RHHBY) nine months  
    Via Benzinga
    News headline image
    What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗
    Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
    Via Benzinga
    News headline image
    Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗
    Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
    Via Benzinga
    News headline image
    Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
    Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
    Via Benzinga
    News headline image
    Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗
    In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
    Via Benzinga
    News headline image
    Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗
    Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
    Via Benzinga
    News headline image
    Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer ↗
    Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... 
    Via Benzinga
    News headline image
    Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗
    The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme 
    Via Benzinga
    News headline image
    Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗
    Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
    Via Benzinga
    News headline image
    Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗
    Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t 
    Via Benzinga
    News headline image
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
    Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
    Via Benzinga
    News headline image
    Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
    Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
    Via Benzinga
    News headline image
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
    The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
    Via Benzinga
    News headline image
    Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗
    Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
    Via Benzinga
    News headline image
    Nvidia Invested $50 million into This AI Drug Discovery Biotech
    Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗
    Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
    Via Benzinga
    News headline image
    Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
    Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
    Via Benzinga
    News headline image
    Agilent Technologies Stock: Ready to Rise off the Floor
    Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
    Via MarketBeat
    News headline image
    DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
    DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
    Via MarketBeat
    News headline image
    Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma ↗
    The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)... 
    Via Benzinga
    News headline image
    New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control ↗
    Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
    Via Benzinga
    News headline image
    Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗
    Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
    Via Benzinga
    News headline image
    Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗
    Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)  
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.